MX2009001208A - Compuestos cristalinos antifungicos. - Google Patents

Compuestos cristalinos antifungicos.

Info

Publication number
MX2009001208A
MX2009001208A MX2009001208A MX2009001208A MX2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A
Authority
MX
Mexico
Prior art keywords
crystalline forms
disorders
compounds
quinazolin
difluorophenyl
Prior art date
Application number
MX2009001208A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Canovas Paredes
Javier Bartroli Orpi
Elies Molins Grau
Anna Roig Serra
Kevin Meyer
Keith Lorimer
Original Assignee
Stiefel Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39082545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009001208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06380225A external-priority patent/EP1887004A1/en
Priority claimed from EP07380186A external-priority patent/EP2009009A1/en
Application filed by Stiefel Laboratories filed Critical Stiefel Laboratories
Publication of MX2009001208A publication Critical patent/MX2009001208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2009001208A 2006-08-07 2007-08-06 Compuestos cristalinos antifungicos. MX2009001208A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83586306P 2006-08-07 2006-08-07
EP06380225A EP1887004A1 (en) 2006-08-07 2006-08-07 Crystalline forms of (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one
US92940807P 2007-06-26 2007-06-26
EP07380186A EP2009009A1 (en) 2007-06-26 2007-06-26 Crystalline antifungal compounds
PCT/US2007/017476 WO2008021049A2 (en) 2006-08-07 2007-08-06 Crystalline antifungal compounds

Publications (1)

Publication Number Publication Date
MX2009001208A true MX2009001208A (es) 2009-04-14

Family

ID=39082545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001208A MX2009001208A (es) 2006-08-07 2007-08-06 Compuestos cristalinos antifungicos.

Country Status (17)

Country Link
US (2) US7879867B2 (cg-RX-API-DMAC10.html)
EP (2) EP2049504A4 (cg-RX-API-DMAC10.html)
JP (3) JP2010513222A (cg-RX-API-DMAC10.html)
KR (1) KR20090053903A (cg-RX-API-DMAC10.html)
CN (1) CN103232442B (cg-RX-API-DMAC10.html)
AR (1) AR062232A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007284851B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0716026A2 (cg-RX-API-DMAC10.html)
CA (1) CA2658843A1 (cg-RX-API-DMAC10.html)
DK (1) DK2650291T3 (cg-RX-API-DMAC10.html)
ES (1) ES2652670T3 (cg-RX-API-DMAC10.html)
IL (2) IL196722A (cg-RX-API-DMAC10.html)
IN (1) IN2014MN01560A (cg-RX-API-DMAC10.html)
MX (1) MX2009001208A (cg-RX-API-DMAC10.html)
RU (1) RU2500679C2 (cg-RX-API-DMAC10.html)
TW (1) TWI426073B (cg-RX-API-DMAC10.html)
WO (1) WO2008021049A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
TWI363058B (en) * 2006-04-05 2012-05-01 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
ITMI20062449A1 (it) * 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
AU2010254064B2 (en) * 2009-05-29 2015-01-22 Palau Pharma, S.L.U Azole antifungal compositions
KR20120079054A (ko) * 2009-07-10 2012-07-11 에볼바 아게 디인 조성물
EP2464230B1 (en) * 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
US9435692B2 (en) 2014-02-05 2016-09-06 Lam Research Corporation Calculating power input to an array of thermal control elements to achieve a two-dimensional temperature output
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
GB201410407D0 (en) * 2014-06-11 2014-07-23 Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med Treatment of chagas disease
EA025187B1 (ru) * 2015-04-17 2016-11-30 Тагир Аббасели оглы Сулейманов Производное дитиокарбамата 2-((4-(4-метилпиперазин-1-ил)фенил)амино)-2-оксоетил4-этилпиперазин-1-карбодитиоат, обладающее антифунгальной активностью
CN118695852A (zh) 2021-12-22 2024-09-24 帕劳制药有限公司 多颗粒阿巴康唑组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293500A1 (en) 1987-06-01 1988-12-07 American Cyanamid Company 3-heteroalkyl-2,4.quinzaoline-diones
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
TW218017B (cg-RX-API-DMAC10.html) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
TW297813B (cg-RX-API-DMAC10.html) * 1993-09-24 1997-02-11 Takeda Pharm Industry Co Ltd
CA2134417A1 (en) * 1993-12-22 1995-06-23 Katsumi Itoh Optically active azole derivatives, their production and use
MX9702382A (es) * 1995-08-02 1998-02-28 Uriach & Cia Sa J Nuevos derivados de pirimidona con actividad antifungica.
WO1998039305A1 (en) * 1997-03-05 1998-09-11 Takeda Chemical Industries, Ltd. Crystalline form of a bis 1,2,4-triazole compound
ES2159488B1 (es) * 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.

Also Published As

Publication number Publication date
AU2007284851A1 (en) 2008-02-21
US7879867B2 (en) 2011-02-01
JP2010513222A (ja) 2010-04-30
TWI426073B (zh) 2014-02-11
US20110092702A1 (en) 2011-04-21
EP2650291A1 (en) 2013-10-16
RU2500679C2 (ru) 2013-12-10
IL196722A (en) 2016-10-31
CA2658843A1 (en) 2008-02-21
WO2008021049A2 (en) 2008-02-21
EP2049504A4 (en) 2010-09-22
EP2650291B1 (en) 2017-10-04
AR062232A1 (es) 2008-10-22
JP2014012673A (ja) 2014-01-23
IL248216B (en) 2018-03-29
WO2008021049A9 (en) 2008-10-30
EP2049504A2 (en) 2009-04-22
TW200823197A (en) 2008-06-01
RU2009104959A (ru) 2010-08-20
IN2014MN01560A (cg-RX-API-DMAC10.html) 2015-05-08
WO2008021049A3 (en) 2008-12-31
IL196722A0 (en) 2009-11-18
ES2652670T3 (es) 2018-02-05
US8258296B2 (en) 2012-09-04
DK2650291T3 (en) 2017-10-23
KR20090053903A (ko) 2009-05-28
CN103232442A (zh) 2013-08-07
CN103232442B (zh) 2015-01-21
AU2007284851B2 (en) 2013-05-09
US20080076787A1 (en) 2008-03-27
BRPI0716026A2 (pt) 2013-08-06
JP2015193642A (ja) 2015-11-05

Similar Documents

Publication Publication Date Title
IN2014MN01560A (cg-RX-API-DMAC10.html)
MY157177A (en) Heteroaryl compounds useful as inhibitors of e1 activating enzymes
SG169369A1 (en) Inhibitors of e1 activating enzymes
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
ATE534632T1 (de) Thiazole, imidazole und pyrazole als proteinkinasehemmer
EP2484679A3 (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
WO2010002779A3 (en) Naphthyridininones as aurora kinase inhibitors
CL2011000480A1 (es) Compuestos derivados de amino-1,2,4-triazolo[1,5-a]piridina sustituidos, inhibidores de quinasa; composicion farmaceutica; y su uso para el tratamiento o prevencion de condiciones inflamatorias, inmunologicas, autoinmunes, alergicas, reumaticas, tromboticas, cancer, infecciones, padecimientos neurodegenerativos, entre otras.
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MY143000A (en) 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
WO2009012109A3 (en) Cyanine-containing compounds for cancer imaging and treatment
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
WO2007097981A3 (en) Alpha carbolines and uses thereof
SG10201804842WA (en) Tropomyosin-related kinase (trk) inhibitors
WO2017155942A3 (en) Substituted heterocycles as c-myc targeting agents

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PALAU PHARMA, S.A.

FG Grant or registration